Multifactorial genesis of enhanced platelet aggregability in patients with nephrotic syndrome. Platelet aggregation, I.3-thromboglobulin (/3-TG) and platelet factor 4 (PF 4) release and thromboxane B2 (TxB2) formation in stimulated platelet-rich plasma were investigated in 13 patients with nephrotic syndrome who had normal serum creatinine levels (creatinine clearance >70 ml/min/l.73 m2). In contrast to 13 sexand age-matched controls, spontaneous platelet aggregation only occurred in patients with nephrotic syndrome with correlation to serum albumin and plasma fibrinogen levels. The EC50 (estimated concentration of aggregating agent to cause half maximum velocity of primary aggregation) for ADP and collagen and threshold concentration of arachidonic acid (threshold AA) were decreased in patients with nephrotic syndrome, reflecting a hyperaggregable state. In patients with nephrotic syndrome EC50 ADP values were significantly correlated to serum albumin, serum cholesterol and plasma fibrinogen, however, EC50 collagen or threshold AA did not correlate to these parameters. Plasma f3-TG levels were increased in patients, whereas plasma PF 4 levels were not significantly changed in patients compared to controls. In vitro TxB2 formation was elevated in patients only after stimulation with AA. Nevertheless, after stimulation with collagen and ADP, TxB2 formation was unchanged in patients compared to controls. Platelet hyperaggregability in nephrotic patients was confirmed in our study. However, unchanged thromboxane B2 formation after collagen stimulus as well as missing correlations between EC50 collagen or threshold AA and serum albumin were contradictory to the hypothesis that enhanced AA availability due to hypoalbuminemia is responsible for platelet hyperaggregability. Platelet hyperaggregability in terms of EC50 ADP being associated with serum albumin levels as well as to serum cholesterol and plasma fibrinogen indicate a multifactorial genesis.
Multifactorial genesis of enhanced platelet aggregability in patients with nephrotic syndrome. Platelet aggregation, I.3-thromboglobulin (/3-TG) and platelet factor 4 (PF 4) release and thromboxane B2 (TxB2) formation in stimulated platelet-rich plasma were investigated in 13 patients with nephrotic syndrome who had normal serum creatinine levels (creatinine clearance >70 ml/min/l.73 m2). In contrast to 13 sexand age-matched controls, spontaneous platelet aggregation only occurred in patients with nephrotic syndrome with correlation to serum albumin and plasma fibrinogen levels. The EC50 (estimated concentration of aggregating agent to cause half maximum velocity of primary aggregation) for ADP and collagen and threshold concentration of arachidonic acid (threshold AA) were decreased in patients with nephrotic syndrome, reflecting a hyperaggregable state. In patients with nephrotic syndrome EC50 ADP values were significantly correlated to serum albumin, serum cholesterol and plasma fibrinogen, however, EC50 collagen or threshold AA did not correlate to these parameters. Plasma f3-TG levels were increased in patients, whereas plasma PF 4 levels were not significantly changed in patients compared to controls. In vitro TxB2 formation was elevated in patients only after stimulation with AA. Nevertheless, after stimulation with collagen and ADP, TxB2 formation was unchanged in patients compared to controls. Platelet hyperaggregability in nephrotic patients was confirmed in our study. However, unchanged thromboxane B2 formation after collagen stimulus as well as missing correlations between EC50 collagen or threshold AA and serum albumin were contradictory to the hypothesis that enhanced AA availability due to hypoalbuminemia is responsible for platelet hyperaggregability. Platelet hyperaggregability in terms of EC50 ADP being associated with serum albumin levels as well as to serum cholesterol and plasma fibrinogen indicate a multifactorial genesis.
Venous and arterial thromboses are common and well known complications in patients with nephrotic syndrome. Several investigations have confirmed a state of hypercoagulability due to increased production of clotting factors, a reduced fibrinolytic activity and renal loss of antithrombin III [1-31. In addition platelet hyperaggregability occurs in nephrotic syndrome [4, 5] . Though there are contradictory results [6] , some studies have revealed a negative correlation of serum albumin with the incidence of thrombosis [7] as well as with platelet hyperaggregability [7] [8] [9] [10] .
Platelet hyperaggregability is evident in an enhanced response of nephrotic platelets to stimulation with ADP, epinephReceived for publication October 12, 1988 and in revised form June 26, 1989 Accepted for publication June 29, 1989 o 1989 by the International Society of Nephrology rine, collagen or arachidonic acid [4, 8, [10] [11] [12] [13] [14] as well as in increased /3-thromboglobulin levels [7, 14, 15] .
Platelet hyperaggregability in nephrotic syndrome also coincides with an enhanced thromboxane B2 or malondialdehyde formation after addition of arachidonic acid [10, 16] , collagen [5] or thrombin [11] to platelet rich plasma. Platelet function after stimulation with arachidonic acid normalizes after correction of hypoalbuminemia in vitro or in vivo. Therefore hypoalbuminemia is thought to modify cyclooxygenase activity by a reduced binding of arachidonic acid. This would lead to an enhanced platelet activity and an increased formation of thromboxane A2 [10, 16] .
To review this pathophysiological concept we studied parameters of platelet aggregability and release reaction in patients with nephrotic syndrome with special regard to thromboxane B2 formation after stimulation with different agents.
Methods

Patients
Thirteen patients with a proteinuria greater than 3.5 g/24 hr/l.73 m2 body surface area [17] were investigated. Patients had normal serum creatinine levels; those with a creatinine clearance below 70 mllminll.73 m2 were excluded as well as those with systemic disease (such as, diabetes mellitus, lupus erythematodes) or on corticosteroid therapy. Percutaneous kidney biopsy specimens were obtained in 11 of 13 patients (Table 1 ) and investigated by light microscopy, electron microscopy and immunofluorescence staining. The patients gave their informed consent to participate in the study.
Controls
Thirteen sex-and age-matched volunteers without proteinuna and with normal renal function, who had denied the ingestion of acetylsalicylic acid or other platelet inhibitors for at least two weeks before the study were investigated as controls.
Blood collection and plasma preparation
For preparation of platelet rich plasma (PRP) blood was collected into 3.13% sodiumcitrate (9:1 vol/vol). Blood was centrifuged 10 minutes at 200 g to obtain PRP and further 10 minutes at 3000 g to obtain platelet poor plasma (PPP). Platelet number in PRP was adjusted to 2 x 101 'Iliter with autologous PPP. During the platelet aggregation study PRP was stored in a plastic syringe to prevent pH instability [18] . Platelet functions are: EC50 ADP (MmolIl); EC50 collagen (g/ml); threshold concentration of arachidonic acid, AA (mmol/l); and spontaneous platelet aggregation, SpA, slope of primary aggregation (%/min).
For measurement of /3-thromboglobulin, blood was collected into two precooled tubes containing EDTA/theophylline (Amersham Buchler, Braunschweig, FRG), acetylsalicylic acid and prostaglandin E1 (Sigma Chemicals, FRO) in a final concentration of 2.5 mmol/liter and 1.0 /Lmol/liter, respectively. After one hour PPP was prepared by centrifugation at 20 minutes x 3000 g at 0°C.
Platelet aggregation studies For ADP and collagen the maximum velocity of primary aggregation was measured in the steepest initial part of the curve. According to Thompson and Vickers [201 the sigmoid relation between log dose of aggregation agent and the primary aggregating rate was fitted by a computer program using the sigmoid E-max-model [21] . The resulting EC50 is the estimated dose of aggregating agent to cause the half maximum response of aggregating velocity.
Spontaneous platelet aggregation was measured in a stirred PRP system by adding 10 d of saline 0.9% to 190 jzl of PRP. The rate of aggregation was expressed as the change in light transmittance in percent per minute. Thromboxane B2 (TXB2) was determined by radioimmunoassay according to Anhut, Bernauer and Peskar [22] . 3H-TXB2 and purified TXBrstandard were from Dr. C.O. Meese (Margarete-Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, FRO). The antibody (AFB, Berlin, FRO) had a good specifity with cross reactions to 6-keto-PGF1a, POD2, POE2, POE1, PGF1Q and PGF2a below 0.05%. /3-thromboglobulin and platelet factor 4 levels Plasma /3-thromboglobulin levels were measured using a radioimmunoassay kit (Amersham Buchier, Braunschweig, FRG). Plasma platelet factor 4 levels were also determined by radioimmunoassay (Abbott Diagnostic Products, Wiesbaden, FRO).
Statistics
Statistic evaluation of results was done by Student's t-test and by linear correlation by least squares.
Results
Thirteen patients with nephrotic syndrome were investigated. The results of renal biopsy and creatinine clearance values of these patients are shown in Table 1 . Compared to 13 sex-and age-matched controls patients showed a significant thombocytosis, hypoalbuminemia, hypercholesterolemia, reduced antithrombin III levels and increased plasma fibrinogen (Table 2) .
Platelet aggregability was investigated by estimated concentrations of aggregating agent to cause half maximal velocity of primary aggregation (EC50) for ADP and collagen, threshold concentrations of arachidonic acid and the rate of spontaneous platelet aggregation. The values of these parameters are listed in Table 1 Linear correlations were calculated between EC50 ADP, EC50 collagen, threshold concentrations of arachidonic acid on the one hand and serum albumin, cholesterol and plasma fibrinogen levels on the other hand. The results are shown in Table 3 . Low EC50 ADP values which indicate an enhanced platelet aggregability were significantly correlated with low serum albumin levels as well as high serum cholesterol and plasma fibrinogen levels. EC50 values for collagen and threshold concentrations of arachidonic acid did not correlate to albumin, cholesterol or fibrinogen levels. Patients with a serum albumin below 2.3 g/dl showed a marked spontaneous aggregation which correlated to serum albumin and plasma fibrinogen. Furthermore, there was a significant intercorrelation between EC50
ADP and spontaneous platelet aggregation (r = -0.702, P = Fig. 2 . Plasma beta.thromboglobulin levels (ng/ml) and plasma platelet factor 4 levels (nglml) detected by radioimmunoassay in patients with nephrotic syndrome (liii) compared with controls () (mean SD, N = 13 each).
0.008). Spontaneous platelet aggregation could not be observed
in patients with higher serum albumin levels as well as in controls. Moreover, f3-thromboglobulin levels were increased in patients compared to controls (47.1 20.7 nglml vs. 24.0 8.3 ng/ml, P = 0.0012, mean sD; Fig. 2 ). PF 4 levels were also elevated in patients compared with controls, however, the result was not statistically significant (7.58 4.46 ng/ml vs. 5.46 3.83 rig/mI, P = 0.204, mean SD, Fig. 2 ).
In vitro thromboxane B2 formation after stimulation with 20 moL/liter ADP, 8 p.g/ml collagen or 1 mmollliter arachidonic acid was detected by radioimmunoassay. After ADP and collagen stimulation there was no significant difference in thromboxane B2 formation between patients and controls (ADP: 2.84 3.14 ng/ml vs. 3.14 2.61 ng/ml, P = 0.79; collagen: 148.3 57.6 ng/ml vs. 172.5 43.4 ng/ml, P = 0.24, means SD).
Thromboxane B2 formation after arachidonic acid stimulus was enhanced in patients compared with controls (711.7 268.6 ng/ml vs. 414.5 115.0 nglml, P = 0.001, means SD, Fig. 3 ).
Discussion
Platelet release products such as f3-thromboglobulin or platelet factor 4 has often been studied as an indicator of platelet hyperaggregability. /3-thromboglobulin levels are known to be elevated in patients with renal failure without nephrotic syndrome or thrombosis [23, 24] . Accordingly, elevation of /3-thromboglobulin levels is due to decreased renal elimination in renal failure subsequently leading to accumulation. In most previous studies elevated /3-thromboglobulin levels were detected in patients with nephrotic syndrome and partially impaired renal function [7, 13, 14] . Thus it was not possible to differentiate between the effects of impaired renal function versus the effects of nephrotic syndrome. As all our patients had a normal serum creatinine (creatinine clearance >70 mu minll .73 m2) elevated /3-thromboglobulin levels in nephrotic syndrome could not be ascribed to impaired renal elimination but may reflect a state of platelet hyperaggregability. These results are in accordance with earlier results of Canavese et al [15] . However, we did not find a correlation of f3-thromboglobulin levels to other parameters of platelet aggregability. As opposed to our results Walter and coworkers [9] found normal /3-thromboglobulin levels in patients with nephrotic syndrome and serum creatinine levels below 1.4 mgldl. Platelet factor 4 levels are known to be independent of renal function and therefore would be a suitable marker for platelet hyperaggregability in patients with renal impairment. Unfortunately, platelet factor 4 levels in patients with nephrotic syndrome did not differ significantly from controls in our study. A earlier study also failed to establish a platelet factor 4 elevation in patients with nephrotic syndrome [13] .
Platelets from patients with nephrotic syndrome have been reported to be hyperaggregable to aggregating agents like ADP, epinephrine, arachidonic acid, collagen or thrombin [3, 4, 8, [10] [11] [12] [13] . However, in most of these studies [3, 4, 8, 12, 13] platelet count in platelet rich plasma (PRP) was not adjusted to a constant value to perform platelet aggregation tests. However, the aggregating response is known to depend on platelet number [25] . Therefore a significant thrombocytosis in patients with nephrotic syndrome compared with controls [1, 6, 9, 13] may have influenced the results of platelet hyperaggregability.
Our data now confirm previous results of enhanced platelet aggregability in adjusted platelet-rich plasma stimulated by ADP, collagen [10, 11] and arachidonic acid [10] .
Standardization of platelet aggregation studies was only established in 1985 by Vickers and Thompson [26] . The estimated concentration of an aggregating agent to cause half maximum velocity of primary aggregation (EC50) was detected by adding up to 10 different concentrations of stimulant. An epidemiological study using this method revealed a high sensitivity and a good reproducibility [27] . We confirmed that platelets from patients with nephrotic syndrome are hyperaggregable to ADP and collagen using the EC50 method in adjusted PRP as well as to arachidonic acid established by measuring threshold concentrations in adjusted PRP. We also found a significant spontaneous aggregation of nephrotic platelets with a good inversed correlation to serum albumin which coincides with earlier results [7, 9] . In a few studies platelet aggregability to epinephrine and ADP [5, 121 and to arachidonic acid [5, 8] could be reversed by correction of hypoalbuminemia. Therefore platelet hyperaggregability seems to be closely associated with hypoalbuminemia. Our data show a correlation between ADP-induced aggregability and hypoalbuminemia as well as between spontaneous platelet aggregation and hypoalbuminemia, which gives support to this hypothesis. Because ADP-induced primary aggregation is independent of cyclooxygenase enzyme [28] , there has to be an association between albumin concentration and ADP-induced platelet aggregation which is not related to platelet prostaglandin metabolism. However, mechanisms are not yet known.
Arachidonic acid metabolism was extensively investigated by Yoshida and Aoki in one patient with nephrotic syndrome [5] . Compared to platelets of a normal donor there was increased platelet malondialdehyde formation in a suspension of washed platelets after stimulation with collagen. This effect was reversible by adding albumin in vitro. Enhanced malondialdehyde formation was also found in six nephrotic children compared with five children with nephrotic syndrome in remission after stimulation with thrombin [11] . It was postulated that platelet hyperaggregability in nephrotic syndrome is caused by elevated arachidonic acid availability to the cyclooxygenase pathway due to reduced binding of arachidonic acid to albumin [8, 10, 16] . Nevertheless we found thromboxane B2 formation unchanged in platelet rich plasma after stimulation with collagen which corresponds with earlier results [10] . This contradiction may be explained by the different experimental conditions of washed platelet suspension on one hand and platelet rich plasma on the other hand.
Studying release of radioactivity from '4C-arachidonic acidlabeled platelets Stuart, Gerard and White [29] found a decreased release of arachidonic acid in the presence of hypoalbuminemia after stimulation with thrombin. However, as hypoalbuminemia leads to an enhanced conversion of this released arachidonic acid by cyclooxygenase the overall conversion of 14C-arachidonic acid to thromboxane B2 remained the same, thus not being dependent on albumin concentration. The effect of varying albumin concentrations on the release of radioactivity from thrombin-treated platelets prelabeled with 5H-arachidonic acid was also studied by Deykin, Russell and Vaillancourt [30] . Only albumin concentrations between 0 and 1.0 mg/mI substantially influenced the release of arachidonic acid and its conversion to cyclooxygenase products. This range of albumin concentrations is about 1/50 of the "physiologic" Further investigations demonstrated an increased thromboxane B2 or malondialdehyde formation respectively only after stimulation with arachidonic acid [10, 16] . This could be reversed by in vitro addition of albumin. As a fatty acid arachidonic acid is bound to albumin. Arachidonic acid used for stimulating a platelet suspension is already bound to the extracellular albumin depending on its concentration. Thus albumin may reduce the effective stimulating concentration of arachidonic acid in a dose-related manner. We therefore believe that the results of arachidonic acid induced platelet aggregation as well as the resulting elevated thromboxane B2 formation in hypoalbuminemia are most likely an in vitro phenomenon.
In contrast to the effect of hypoalbuminemia on platelet aggregation in nephrotic syndrome the relations of hypercholesterolemia or hyperfibrinogenemia to platelet hyperaggregability in nephrotic syndrome are poorly investigated. In our study platelet aggregability measured by EC50 ADP correlated with serum cholesterol levels. An earlier study has already shown a significant correlation of spontaneous platelet aggregation to serum cholesterol levels [91. However, we failed to establish a significant correlation between spontaneous platelet aggregation and serum cholesterol. Hypercholesterolemia is a main symptom of the nephrotic syndrome. Shattil et al [31] demonstrated that the acquisition of cholesterol by platelets in vitro is associated with increased platelet sensitivity to aggregating agents. Also enrichment with cholesterol leads to a increased release of radioactivity in '4C-arachidonic acid labeled platelets from normal donors stimulated with thrombin [32] . Cholesterol is supposed to interfere with diglyceride lipase and phospholipase A2 by affecting membrane fluidity [33] . These enzymes are involved in the release of arachidonic acid from platelet phospholipids [34] .
Furthermore, we found a significant correlation between plasma fibrinogen levels and platelet aggregability determined by EC50 ADP and spontaneous platelet aggregation which has not been investigated in earlier studies so far. Fibrinogen is known to link aggregating platelets through binding to platelet glycoprotein receptor lib/Illa. Within physiologic ranges fibrinogen levels correlate to platelet aggregability in terms of EC50 ADP [35] . High fibrinogen levels are also associated with an increased risk of coronary heart disease and stroke [36] . In participants of the Northwick Park Heart Study [27] increasing platelet aggregability measured by EC50 ADP was shown to correlate with rising plasma fibrinogen concentrations. Our data confirmed a similar correlation in patients with nephrotic syndrome between plasma fibrinogen levels and platelet hyperaggregability.
We do not know which of these in vitro parameters really reflect the in vivo situation of platelet aggregability. According to our data, pronounced platelet hyperaggregability seems to be related to hypoalbuminemia as well as to hypercholesterolemia and high plasma fibrinogen, indicating a multifactorial genesis of platelet hyperaggregability in nephrotic syndrome. Our results point to a disturbance of platelet function which is very likely not dependent on arachidonic acid metabolism. A recent study [37] showed an enhanced ristocetin-induced platelet aggregation in patients with nephrotic syndrome which was not investigated by us. There was no relation between ristocetininduced platelet aggregation and hypoalbuminemia or platelet arachidonic acid metabolism. However, the effect of serum cholesterol levels and plasma fibrinogen levels has not been reported. We conclude that thrombotic risk in patients with nephrotic syndrome may not to be treated with inhibitors of platelet cyclooxygenase.
